semaglutide News
Latest articles and news about semaglutide on AXL Media.
Latest Articles
- Experimental Five-Target Molecule Outperforms Semaglutide in Correcting Obesity and Diabetes in Preclinical Trials
Published: May 1, 2026
Section: Health Technology
Researchers have developed a single-molecule "quintuple agonist" that combines incretin-based signaling with the insulin-sensitizing properties of lanifibranor to treat metabolic d...
- New Clinical Guidelines Advise Nurse Practitioners on Expanding GLP-1 Receptor Agonist Indications and Risks
Published: Apr 28, 2026
Section: Medical News
A comprehensive review published in The Nurse Practitioner details the evolving role of GLP-1 receptor agonists beyond diabetes management into cardiovascular and renal protection....
- Endoscopic "gut reset" procedure prevents weight rebound after stopping Ozempic and Wegovy
Published: Apr 23, 2026
Section: Research
A new minimally invasive technique called duodenal mucosal resurfacing (DMR) could solve the "weight regain" paradox for patients discontinuing GLP-1 medications. Clinical trial re...
- AI Analysis of 400,000 Reddit Posts Uncovers Underreported GLP-1 Side Effects
Published: Apr 11, 2026
Section: Health
Researchers at the University of Pennsylvania have utilized advanced artificial intelligence to identify patient-reported symptoms associated with popular GLP-1 weight-loss and dia...
- AI Analysis of 400,000 Reddit Posts Identifies Unreported Side Effects Linked to Popular GLP-1 Weight-Loss Drugs
Published: Apr 10, 2026
Section: Medical News
University of Pennsylvania researchers utilized large language models to scan over half a decade of social media discussions regarding semaglutide and tirzepatide. The study uncove...
- New Genetic Study Identifies Why Some GLP-1 Users Lose More Weight and Face Higher Side Effect Risks
Published: Apr 10, 2026
Section: Health
A large-scale genome-wide association study (GWAS) involving nearly 28,000 participants has identified specific genetic variants in the GLP1R and GIPR genes that influence a patien...
- Clinical Study Warns of Critically Low Protein Intake and Nutritional Risks for GLP-1 Drug Users
Published: Apr 10, 2026
Section: Medical News
A real-world analysis of adults using GLP-1 receptor agonists, such as semaglutide and tirzepatide, has identified a significant risk of nutritional deficiency due to drastically r...
- New Genetic Study Identifies Why GLP-1 Weight Loss Efficacy and Side Effects Vary Between Patients
Published: Apr 8, 2026
Section: Health Technology
The 23andMe Research Institute has published a large-scale genome-wide association study in Nature identifying genetic markers that predict how individuals respond to GLP-1 medicat...
- Clinical Case Study Reveals Semaglutide Treatment Linked to Near Total Cessation of Alcohol Consumption
Published: Apr 3, 2026
Section: Medical News
A 34-year-old male treated with semaglutide for class 2 obesity experienced a dramatic reduction in alcohol dependency, with his intake dropping from 15 drinks weekly to nearly zer...
- FDA Grants Approval for High-Dose Wegovy as Novo Nordisk Battles Eli Lilly for Weight-Loss Dominance
Published: Apr 2, 2026
Section: Science & Tech
The Food and Drug Administration has approved a 7.2-milligram dose of Novo Nordisk’s weight-loss injection, Wegovy, aimed at closing the efficacy gap with rival medications. Clinic...
- Two Major Phase 3 Trials Confirm Oral Semaglutide Fails to Slow Cognitive Decline in Early Alzheimer’s Patients
Published: Mar 23, 2026
Section: Health
Results from the global "evoke" and "evoke+" clinical trials published in The Lancet show that oral semaglutide does not meaningfully delay the progression of early-stage Alzheimer...
- Large-Scale Registry Study Links GLP-1 Medications to 42% Reduction in Psychiatric Hospitalizations and Sickness Absence
Published: Mar 19, 2026
Section: Science & Tech
A collaborative study involving nearly 100,000 participants has found that GLP-1 receptor agonists, specifically semaglutide, are associated with a significant decrease in hospital...